Skip to content
Screener

NovoCure NVCR EPS (Diluted)

EPS (Diluted) at other companies

Boston Scientific logo
Boston ScientificBSX
$0.61+15.1%
Medtronic logo
MedtronicMDT
$0.97+18.3%
Nuvation Bio logo
Nuvation BioNUVB
-$0.18-5.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$0.11+66.7%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$0.12-300%
AngioDynamics logo
AngioDynamicsANGO
-$0.27-80.0%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025Year ended December 31, 2025
Total operating costs and expenses153,040156,854355,586311,192642,274
Operating income (loss)(10,562)(39,521)(77,982)(77,386)(153,800)
Financial income (expenses), net(1,890)4,542(3,728)12,11217,550
Income (loss) before income tax(12,452)(34,979)(81,710)(65,274)(136,250)
Income tax3,2065,1605,0869,184(23)
Net income (loss)$(15,658)$(40,139)$(86,796)$(74,458)$(136,227)
Basic and diluted net income (loss) per ordinary share$(0.13)$(0.36)$(0.75)$(0.67)$(1.22)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share116,012,397111,572,191115,106,850110,930,576111,471,991

Item 1. Financial Statements

FAQ

What is NovoCure's EPS (diluted)?
NovoCure (NVCR) reported EPS (diluted) of -$0.13 in Q2 2026.
How has NovoCure's EPS (diluted) changed year-over-year?
NovoCure's EPS (diluted) increased by 63.9% year-over-year, from -$0.36 to -$0.13.
What is the long-term trend for NovoCure's EPS (diluted)?
Over 4 years (2021 to 2025), NovoCure's EPS (diluted) has grown at a 21.5% compound annual growth rate (CAGR), from -$0.56 to -$1.22.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about NovoCure's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude